Session III: September 20, 2023

Enhancing Clinical Trial Awareness and Increasing Participation of Black Patients

Successful prostate cancer clinical trials have ushered in a new generation of treatment therapies. However, the lack of participation in these trials by Black patients was a significant missed opportunity.  This session will highlight some of the missed opportunities and present strategies by trial sponsors to diversify their trials. The session will also include patients’ testimonials about their clinical trial experiences and needs. PHEN’s Clinical Trials rally will showcase PHENs efforts to increase clinical trial awareness and participation by Black patients.

Prior Summit Images

Session III Agenda

Welcome and Opening Remarks: Mr. Thomas Farrington, President and Founder, PHEN

Moderator: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN

Clinical Trial Successes and Missed Opportunities: Richard Lee, MD, PhD, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center

Strategies to Diversify Patients’ Participation in Clinical Trials

      • Pfizer: Ms. Sandra Amaro, MBA, Head of Clinical Trial Diversity
      • Merck: Ms. Cameron Davis, Associate Director, Clinical Trial Diversity
      • Novartis: Ms. Kim Fookes, Global Head, Diversity and Inclusion in Clinical Trials, Global Development
      • Janssen: Ms. Lisa Lewis, Director, Diversity, Equity & Inclusion in Clinical Trials – Oncology
      • Prostate Cancer Clinical Trials Consortium: Ms. Natalie Macario, Promise Project Associate
      • Macrogenics: Ms. Amy Worth, Associate Director in Clinical Operations

Prostate Cancer Patients’ Clinical Trials Experiences

PHEN’s Strategies to Increase Patient Awareness and Participation: Dr. Keith Crawford

Closing Remarks: Mr. Thomas Farrington


PHEN thanks its sponsors for their support of the 2023 Summit.